Background
Goflikicept (RPH 104) is a fusion protein that selectively binds and inactivates both circulating IL-1β and IL-1α. Goflikicept has the potential for the research of ST-segment elevation myocardial infarction (STEMI).• Bacterial Endotoxin Activates the Coagulation Cascade through Gasdermin D-Dependent Phosphatidylserine Exposure., PMID:31836429• Phase 3 Trial of Interleukin-1 Trap Rilonacept in Recurrent Pericarditis., PMID:33200890• Deconvolution of monocyte responses in inflammatory bowel disease reveals an IL-1 cytokine network that regulates IL-23 in genetic and acquired IL-10 resistance., PMID:33037057• The interactions between interleukin-1 family genes: IL1A, IL1B, IL1RN, and obesity parameters., PMID:35139823• Targeting IL-1β in the Treatment of Atherosclerosis., PMID:33362770• IL-1 family cytokines in cardiovascular disease., PMID:29198612• Potential of cannabidiol as acne and acne scar treatment: novel insights into molecular pathways of pathophysiological factors., PMID:38904694• IL1A and IL1B gene polymorphisms and keratoconus susceptibility: evidence from an updated meta-analysis., PMID:33978542• Association between the IL-1A, IL-1B and IL-1R polymorphisms and lymphoma., PMID:34159887• Roles of IL-1 in Cancer: From Tumor Progression to Resistance to Targeted Therapies., PMID:32825489